Type 2 Diabetes
Conditions
Brief summary
The purpose of this study is to evaluate the effect of BKR-017 on insulin resistance in type 2 diabetes (T2D) subjects during 28 days of active test product administration.
Detailed description
The study consists of a screening period followed by a 28-day treatment period. All subjects will receive test product. There are a total of 4 study visits including screening. Visit 1 is the screening visit. Eligible subject must have an HbA1c between 6.5 -10.5% and with HOMA-IR ≥ 2.7 (calculated from fasting insulin and fasting glucose). Visits 2 and 4 are overnight visits during which time a Mixed Meal Tolerance (MMTT) will be performed after an overnight fast. The MMTT requires an indwelling IV catheter so that 11 blood draws can be more comfortably be obtained over a period of 4 hours. At Visit 3,subjects will be evaluated and test product will be replenished. Routine chemistry and hematology testing are done and two time periods during the study and a physical exam is performed at screening
Interventions
DIETARY_SUPPLEMENTBKR-017
BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
Sponsors
BioKier Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females between the ages of 18 and 70 years at the time of screening, inclusive 2. Diagnosed with T2D and under the care of a healthcare professional for its management 3. HbA1c 6.5-10.5%, inclusive 4. HOMA-IR 2.7 and above 5. Has given written informed consent to participate in this study 6. Willing to complete 28-day test period, including two overnight stays 7. Willing to maintain current diet and exercise routine and current prescription medications for the duration of the study
Exclusion criteria
1. Type 1 diabetes 2. History of bariatric or intestinal surgery 3. Active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), diverticulitis, gastroparesis, or chronic/frequent diarrhea or chronic/frequent constipation 4. Active and clinically significant hepatic, pancreatic disease, or renal disease as determined by the investigator 5. History of significant heart disease, including congestive heart failure, prior MI, chronic atrial or ventricular fibrillation, coronary artery disease, cerebral vascular disease or other cardiovascular disease, that in the opinion of the investigator should exclude the subject from the study 6. Severely uncontrolled hypertension at screening defined as a systolic blood pressure \> 180 mmHg or a diastolic blood pressure \> 110 mmHg on the average of two seated measurements after being at rest for at least 5 minutes 7. Uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease 8. Active significant infection as determined by the investigator 9. Known allergy to butyrate or any of the components of the tablets 10. Participation in a clinical trial and/or treatment with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer) 11. Allergy or intolerance to Boost® High Protein drink 12. Pregnant, nursing, or trying to become pregnant 13. Presence of pitting edema on physical exam 14. High fiber diet 15. In the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study. 16. Subject is taking one or more of the excluded therapies. See list of excluded therapies in section 4.4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin resistance (HOMA-IR) | 28 days of active test product administration | Changes, Day 0 to Day 28 in patient's insulin resistance (HOMA-IR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting insulin | Day 0 to Day 28 | Changes in fasting insulin |
| Fasting triglycerides | Day 0 to Day 28 | Changes in fasting triglycerides |
| Fasting glucose | Day 0 to Day 28 | Changes in fasting glucose |
| Triglyceride, glucose, and insulin AUCs | 4 hours in the MMTT | Changes in triglyceride, glucose, and insulin AUCs |
Countries
United States
Outcome results
None listed